Clinical Trials
276 trialsStudy of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
SIMONE
Yale University
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
National Cancer Institute (NCI)
ACTengine
Immatics US, Inc.
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
National Cancer Institute (NCI)
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
National Cancer Institute (NCI)
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
LIMIT
Abramson Cancer Center at Penn Medicine
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb
REACTION
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Washington University School of Medicine
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
M.D. Anderson Cancer Center
Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
University of Wisconsin, Madison
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
TEADCO
Orion Corporation, Orion Pharma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
T-DXd_HER2Low
National Cancer Center Hospital East
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
A Study of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy
University of Pittsburgh
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
CPIT001
Hackensack Meridian Health
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Metro-PD1
Centre Oscar Lambret
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Perspective Therapeutics
PRiME II
Washington University School of Medicine
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Big Ten Cancer Research Consortium
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies
M.D. Anderson Cancer Center
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
RELATIVITY-069
Bristol-Myers Squibb
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Medical University of South Carolina
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.